PE20070495A1 - COMPUESTOS DERIVADOS DE alfa-AMINOCARBOXIAMIDA CUATERNARIOS COMO MODULADORES DE LOS CANALES DE SODIO CON APERTURA POR VOLTAJE - Google Patents
COMPUESTOS DERIVADOS DE alfa-AMINOCARBOXIAMIDA CUATERNARIOS COMO MODULADORES DE LOS CANALES DE SODIO CON APERTURA POR VOLTAJEInfo
- Publication number
- PE20070495A1 PE20070495A1 PE2006001224A PE2006001224A PE20070495A1 PE 20070495 A1 PE20070495 A1 PE 20070495A1 PE 2006001224 A PE2006001224 A PE 2006001224A PE 2006001224 A PE2006001224 A PE 2006001224A PE 20070495 A1 PE20070495 A1 PE 20070495A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- methyl
- modulators
- voltage
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 108010052164 Sodium Channels Proteins 0.000 title abstract 2
- 102000018674 Sodium Channels Human genes 0.000 title abstract 2
- -1 4 - {[(2-FLUOROPHENYL) METHYL] OXY} PHENYL Chemical class 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520578A GB0520578D0 (en) | 2005-10-10 | 2005-10-10 | Novel compounds |
| GB0523030A GB0523030D0 (en) | 2005-11-11 | 2005-11-11 | Novel compounds |
| GB0603897A GB0603897D0 (en) | 2006-02-27 | 2006-02-27 | Novel compounds |
| GB0609159A GB0609159D0 (en) | 2006-05-09 | 2006-05-09 | Novel Compounds |
| GB0618511A GB0618511D0 (en) | 2006-09-20 | 2006-09-20 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070495A1 true PE20070495A1 (es) | 2007-05-17 |
Family
ID=37762326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001224A PE20070495A1 (es) | 2005-10-10 | 2006-10-06 | COMPUESTOS DERIVADOS DE alfa-AMINOCARBOXIAMIDA CUATERNARIOS COMO MODULADORES DE LOS CANALES DE SODIO CON APERTURA POR VOLTAJE |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7803833B2 (enExample) |
| EP (1) | EP1934176B1 (enExample) |
| JP (1) | JP5139306B2 (enExample) |
| KR (1) | KR20080059297A (enExample) |
| AR (1) | AR057869A1 (enExample) |
| AT (1) | ATE543797T1 (enExample) |
| AU (1) | AU2006301471A1 (enExample) |
| BR (1) | BRPI0617189A2 (enExample) |
| CA (1) | CA2625763A1 (enExample) |
| CR (1) | CR9926A (enExample) |
| EA (1) | EA200801068A1 (enExample) |
| ES (1) | ES2381686T3 (enExample) |
| IL (1) | IL190544A (enExample) |
| NO (1) | NO20082122L (enExample) |
| NZ (1) | NZ567030A (enExample) |
| PE (1) | PE20070495A1 (enExample) |
| TW (1) | TW200728258A (enExample) |
| WO (1) | WO2007042240A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (en) * | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| DK2477964T5 (en) | 2009-09-14 | 2015-05-26 | Convergence Pharmaceuticals | A process for the preparation of alpha-carboxamide |
| JP2011232320A (ja) * | 2009-10-01 | 2011-11-17 | Sony Corp | 生体内物質検出用プローブ、および該生体内物質検出用プローブを用いた生体内物質検出装置 |
| CA2828456C (en) | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| GB201209670D0 (en) * | 2012-05-31 | 2012-07-18 | Convergence Pharmaceuticals | Novel compounds |
| WO2016102967A1 (en) * | 2014-12-23 | 2016-06-30 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| US9624169B2 (en) | 2015-03-27 | 2017-04-18 | Scifluor Life Sciences, Inc. | Aryl- and heteroaryl-pyrrolidine-2-carboxamide compounds |
| EP3691634A4 (en) | 2017-10-05 | 2021-03-31 | Biogen Inc. | PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES |
| MX2020003821A (es) | 2017-10-10 | 2023-01-12 | Biogen Inc | Proceso de elaboración de espiroderivados. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| IL145508A0 (en) | 1999-03-26 | 2002-06-30 | Euro Celtique Sa | Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same |
| AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
| PA8583001A1 (es) | 2002-09-20 | 2004-04-23 | Hoffmann La Roche | Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| CA2520804A1 (en) | 2003-04-03 | 2004-10-28 | Merck & Co., Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
| CA2522476A1 (en) | 2003-04-18 | 2004-11-04 | Merck & Co., Inc. | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| US20060217365A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating mood disorders |
| EP1524265A1 (en) | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| JP2008540443A (ja) | 2005-05-04 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン |
| EP1877381A1 (en) | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| WO2006124865A2 (en) | 2005-05-19 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Biaryls derivatives useful as modulators of ion channels |
| US8093268B2 (en) | 2007-01-24 | 2012-01-10 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-10-05 TW TW095136996A patent/TW200728258A/zh unknown
- 2006-10-06 WO PCT/EP2006/009732 patent/WO2007042240A1/en not_active Ceased
- 2006-10-06 PE PE2006001224A patent/PE20070495A1/es not_active Application Discontinuation
- 2006-10-06 JP JP2008534911A patent/JP5139306B2/ja not_active Expired - Fee Related
- 2006-10-06 EP EP06806111A patent/EP1934176B1/en active Active
- 2006-10-06 KR KR1020087011273A patent/KR20080059297A/ko not_active Withdrawn
- 2006-10-06 EA EA200801068A patent/EA200801068A1/ru unknown
- 2006-10-06 BR BRPI0617189-3A patent/BRPI0617189A2/pt not_active IP Right Cessation
- 2006-10-06 NZ NZ567030A patent/NZ567030A/en unknown
- 2006-10-06 US US11/570,564 patent/US7803833B2/en active Active
- 2006-10-06 ES ES06806111T patent/ES2381686T3/es active Active
- 2006-10-06 AU AU2006301471A patent/AU2006301471A1/en not_active Abandoned
- 2006-10-06 CA CA002625763A patent/CA2625763A1/en not_active Abandoned
- 2006-10-06 AT AT06806111T patent/ATE543797T1/de active
- 2006-10-09 AR ARP060104440A patent/AR057869A1/es active IP Right Grant
-
2008
- 2008-03-31 IL IL190544A patent/IL190544A/en active IP Right Grant
- 2008-04-25 CR CR9926A patent/CR9926A/es not_active Application Discontinuation
- 2008-05-06 NO NO20082122A patent/NO20082122L/no not_active Application Discontinuation
-
2010
- 2010-08-04 US US12/850,330 patent/US8153623B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8153623B2 (en) | 2012-04-10 |
| BRPI0617189A2 (pt) | 2011-07-19 |
| CA2625763A1 (en) | 2007-04-19 |
| US7803833B2 (en) | 2010-09-28 |
| JP5139306B2 (ja) | 2013-02-06 |
| ES2381686T3 (es) | 2012-05-30 |
| US20080293753A1 (en) | 2008-11-27 |
| NO20082122L (no) | 2008-07-02 |
| ATE543797T1 (de) | 2012-02-15 |
| AU2006301471A1 (en) | 2007-04-19 |
| CR9926A (es) | 2008-07-29 |
| JP2009514801A (ja) | 2009-04-09 |
| NZ567030A (en) | 2011-03-31 |
| AR057869A1 (es) | 2007-12-26 |
| EP1934176B1 (en) | 2012-02-01 |
| US20100324022A1 (en) | 2010-12-23 |
| IL190544A0 (en) | 2008-11-03 |
| EP1934176A1 (en) | 2008-06-25 |
| EA200801068A1 (ru) | 2009-02-27 |
| WO2007042240A1 (en) | 2007-04-19 |
| IL190544A (en) | 2013-06-27 |
| KR20080059297A (ko) | 2008-06-26 |
| TW200728258A (en) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080418A1 (es) | Compuestos y composiciones como moduladores de la via de hedgehog | |
| PE20080830A1 (es) | Compuestos derivados de sulfonilo que modulan el receptor cb2 | |
| PE20080348A1 (es) | Moduladores tiazolopirimidina de trpv1 | |
| PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| PE20090477A1 (es) | Derivados de oxazol como inhibidores de los canales de sodio | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| NO20065830L (no) | Substituerte 2-kinolyloksazoler som er anvendbare som PDE4-inhibitorer. | |
| ATE537169T1 (de) | Piperidin- und piperazinderivate als p2x3- antagonisten | |
| PE20080925A1 (es) | DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA) | |
| PE20141041A1 (es) | Compuestos, metodos y formulaciones parasiticidas | |
| PE20091573A1 (es) | Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa | |
| PE20050864A1 (es) | Compuestos de heterociclilamino como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| PE20080154A1 (es) | Derivados de benzamida como moduladores de hidroxiesteroide deshidrogenasas | |
| TW200738696A (en) | Isoxazolines for controlling invertebrate pests | |
| PE20040987A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
| PE20120008A1 (es) | Derivados de fenoxi bencenosulfonamida | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| TW200745117A (en) | Macrocylic inhibitors of hepatitis C virus | |
| PE20081504A1 (es) | Compuestos de biciclocarboxiamida sustituidos | |
| PE20070137A1 (es) | Compuestos derivados de benzamidina como moduladores de las hidroxiesteroide deshidrogenasas | |
| DE602005016775D1 (de) | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion | |
| PE20110299A1 (es) | Nuevos derivados de acilaminobenzamida | |
| DK1633340T3 (da) | Forbindelser til behandling af stofskifteforstyrrelser | |
| PE20050732A1 (es) | Antibioticos de oxazolidinona sustituidos con un grupo ciclopropilo y derivados de los mismos | |
| ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |